ProMIS Neurosciences Presents Data on Novel Vaccine Approaches for ALS, Parkinson's
Event summary
- ProMIS Neurosciences will present data at the AD/PD™ 2026 conference in Copenhagen, Denmark, March 20, 2026.
- Two presentations will focus on a vaccine against TDP-43 proteinopathies and a vaccine targeting alpha-synuclein.
- Neil Cashman and Johanne Kaplan will lead the presentations, with contributions from multiple authors.
- The company's EpiSelect™ platform is central to the development of these vaccine candidates.
The big picture
ProMIS Neurosciences' focus on vaccines targeting misfolded proteins represents a shift from traditional antibody therapies in neurodegenerative disease, a field with a high failure rate. While the EpiSelect™ platform offers a unique approach, the inherent complexity of neurodegenerative diseases and the challenges of vaccine development pose significant hurdles. The data presented at AD/PD™ 2026 will be crucial in assessing the viability of this strategy and its potential to disrupt the current therapeutic landscape.
What we're watching
- Clinical Validation
- The efficacy of the presented vaccine approaches will hinge on subsequent preclinical and clinical trial data, particularly given the challenges in neurodegenerative disease therapeutics.
- Regulatory Pathway
- The FDA’s acceptance of a novel vaccine approach targeting misfolded proteins, especially given the complexity of the underlying biology, remains a key uncertainty.
- Competitive Landscape
- The success of ProMIS's EpiSelect™ platform and its resulting therapies will be weighed against competing approaches from other biotechnology companies targeting neurodegenerative diseases.
Related topics